Investigating the Hypoglycemic Effect of Methylsulfonylmethane in Rabbits
DOI:
https://doi.org/10.5281/zenodo.20961262Keywords:
Diabetes mellitus, Alloxan, Metformin, MSMAbstract
Diabetes is a global health challenge, and as a chronic disease, it requires safe and effective long-term treatments. This study investigated the glucose-lowering effects of methylsulfonylmethane (MSM) compared with metformin in a model of alloxan-induced diabetes. Alloxan selectively destroys pancreatic beta cells, leading to decreased insulin secretion and hyperglycemia. Four groups of rabbits (4 per group) were used: control, alloxan, metformin, and MSM groups. Fasting blood glucose levels were measured 24 hours after the end of dosing for all groups. MSM and metformin significantly reduced hyperglycemia, but MSM showed better results compared to metformin, possibly due to its protective effects on pancreatic beta cells. The study concludes that MSM may be a good therapeutic alternative or additional to established diabetes drugs such as metformin, and we recommend conducting histopathological studies on pancreatic cells to further confirm our results.
Downloads
References
[1] A. Sapra and P. Bhandari, “Diabetes,” in StatPearls. Treasure Island, FL, USA: StatPearls Publishing, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK551501/
[2] M. J. Hossain, M. Al-Mamun, and M. R. Islam, “Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused,” Health Science Reports, vol. 7, no. 3, Art. no. e2004, 2024, doi: 10.1002/hsr2.2004.
[3] J. L. Ríos, F. Francini, and G. R. Schinella, “Natural products for the treatment of type 2 diabetes mellitus,” Planta Medica, vol. 81, no. 12/13, pp. 975–994, 2015, doi: 10.1055/s-0035-1546131.
[4] A. Rohilla and S. Ali, “Alloxan induced diabetes: Mechanisms and effects,” International Journal of Research in Pharmaceutical and Biomedical Sciences, vol. 3, no. 2, pp. 819–823, 2012.
[5] S. Lenzen, “The mechanisms of alloxan- and streptozotocin-induced diabetes,” Diabetologia, vol. 51, no. 2, pp. 216–226, 2008, doi: 10.1007/s00125-007-0886-7.
[6] O. M. Ighodaro, A. M. Adeosun, and O. A. Akinloye, “Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies,” Medicina, vol. 53, no. 6, pp. 365–374, 2017, doi: 10.1016/j.medici.2018.02.001.
[7] C. Baker, C. Retzik-Stahr, V. Singh, R. Plomondon, V. Anderson, and N. Rasouli, “Should metformin remain the first-line therapy for treatment of type 2 diabetes?,” Therapeutic Advances in Endocrinology and Metabolism, vol. 12, Art. no. 2042018820980225, 2021, doi: 10.1177/2042018820980225.
[8] G. Rena, D. G. Hardie, and E. R. Pearson, “The mechanisms of action of metformin,” Diabetologia, vol. 60, no. 9, pp. 1577–1585, 2017, doi: 10.1007/s00125-017-4342-z.
[9] N. F. Wiernsperger and C. J. Bailey, “The antihyperglycaemic effect of metformin: Therapeutic and cellular mechanisms,” Drugs, vol. 58, Suppl. 1, pp. 31–39, 1999, doi: 10.2165/00003495-199958001-00009.
[10] V. R. Aroda et al., “Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study,” The Journal of Clinical Endocrinology & Metabolism, vol. 101, no. 4, pp. 1754–1761, 2016, doi: 10.1210/jc.2015-3754.
[11] I. Sousa-Lima et al., “Methylsulfonylmethane (MSM), an organosulfur compound, is effective against obesity-induced metabolic disorders in mice,” Metabolism, vol. 65, no. 10, pp. 1508–1521, 2016, doi: 10.1016/j.metabol.2016.07.007.
[12] M. Butawan, R. L. Benjamin, and R. J. Bloomer, “Methylsulfonylmethane: Applications and safety of a novel dietary supplement,” Nutrients, vol. 9, no. 3, Art. no. 290, 2017, doi: 10.3390/nu9030290.
[13] R. K. Velusamy and R. Tamizhselvi, “Protective effect of methylsulfonylmethane in caerulein-induced acute pancreatitis and associated lung injury in mice,” Journal of Pharmacy and Pharmacology, vol. 70, no. 9, pp. 1188–1199, 2018, doi: 10.1111/jphp.12946.
[14] L. Miller et al., “The effect of daily methylsulfonylmethane (MSM) consumption on high-density lipoprotein cholesterol in healthy overweight and obese adults: A randomized controlled trial,” Nutrients, vol. 13, no. 10, Art. no. 3620, 2021, doi: 10.3390/nu13103620.
[15] M. Banasova, K. Valachová, I. Juránek, and L. Soltes, “Aloe vera and methylsulfonylmethane as dietary supplements: Their potential benefits for arthritic patients with diabetic complications,” Journal of Information, Intelligence and Knowledge, vol. 5, no. 1, pp. 51–59, 2013.
[16] S. A. Al Laham, “Methylsulfonylmethane (MSM) as a new target for the treatment of glycerol-induced nephropathy,” Journal of Pharmacy and Nutrition Sciences, vol. 8, no. 3, pp. 137–143, 2018.
[17] J. B. Buse et al., “The primary glucose-lowering effect of metformin resides in the gut, not the circulation: Results from short-term pharmacokinetic and 12-week dose-ranging studies,” Diabetes Care, vol. 39, no. 2, pp. 198–205, 2016, doi: 10.2337/dc15-0488.
[18] K. Hieshima et al., “High frequency of defecation under metformin use may be a potential glucose-lowering factor independent of the dose-dependent effect of metformin in patients with type 2 diabetes mellitus,” Internal Medicine, vol. 64, no. 10, pp. 1485–1495, 2025, doi: 10.2169/internalmedicine.3982-24.
[19] J. Pichette and J. Gagnon, “Implications of hydrogen sulfide in glucose regulation: How H2S can alter glucose homeostasis through metabolic hormones,” Oxidative Medicine and Cellular Longevity, vol. 2016, Art. no. 3285074, 2016, doi: 10.1155/2016/3285074.
[20] L. Zhang, G. Yang, A. Untereiner, Y. Ju, L. Wu, and R. Wang, “Hydrogen sulfide impairs glucose utilization and increases gluconeogenesis in hepatocytes,” Endocrinology, vol. 154, no. 1, pp. 114–126, 2013, doi: 10.1210/en.2012-1658.
Downloads
Published
License
Copyright (c) 2025 Journal of Al-Wataniya Private University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
